9th Jun 2016 17:56
RNS : FOR IMMEDIATE RELEASE | 9 JUNE 2016
|
ImmuPharma PLC
("ImmuPharma" or the "Company")
TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Aviva plc and its subsidiaries, ("Aviva") confirming changes to its direct and indirect interest level. Aviva's holding in ImmuPharma remains at a total of 11,285,180 Ordinary Shares which equates to a current position in the Company of 9.27%.
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Immupharma plc | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | |||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | CHANGE IN NATURE : SHARES LOANED OUT
| √ | |||
3. Full name of person(s) subject to thenotification obligation: iii | Aviva plc & its subsidiaries | ||||
4. Full name of shareholder(s) (if different from 3.):iv | Registered Holder:
BNY Norwich Union Nominees Limited 628,858*
Chase (GA Group) Nominees Limited 7,677,826*
State Street Nominees Limited 1,413,511*
*denotes direct interest
Chase (GA Group) Nominees Limited 661,222
Chase Nominees Limited 275,292
Vidacos Nominees Limited 528,471
| ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 7 June 2016 | ||||
6. Date on which issuer notified: | 8 June 2016 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 8% to 7% Change at Direct Interest Level (Box 8a) | ||||
8. Notified details: | ||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||
Ordinary Shares
GB0033711010 | 11,285,180 | 11,285,180 | 11,185,180 | 9,720,195 | 1,464,985 | 7.98% | 1.21% | |||
B: Qualifying Financial Instruments | ||||||||||
Resulting situation after the triggering transaction | ||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||
RIGHT TO RECALL LOANED SHARES | N/A | N/A | 100,000*
* Direct Interest | 0.08% | ||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
11,285,180 | 9.27% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.
| |
14. Contact name: | Neil Whittaker, Aviva plc | |
15. Contact telephone number: | 01603 684420 | |
-Ends-
For further information please contact:
|
Related Shares:
AvivaImmupharma